AbbVie (NYSE:ABBV) stock price target upped to $70.00, released a report earlier today by Leerink Partners
- Updated: October 18, 2016
Reporting a potential upside of 0.16%, Leerink Partners bumped up the target of AbbVie (NYSE:ABBV) to $70.00
On 09/28/2016, Zacks Investment Research released a statement on AbbVie (NYSE:ABBV) upped the target price from $0.00 to $72.00 that suggested an upside of 0.13%.
Having a price of $60.14, AbbVie (NYSE:ABBV) traded 2.34% higher on the day. With the last close down -1.96% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. AbbVie has recorded a 50-day average of $63.38 and a two hundred day average of $62.78. Volume of trade was up over the average, with 6,647,675 shares of ABBV changing hands over the typical 6,256,230
With a total market value of $0, AbbVie has price-earnings ratio of 17.75 with a one year low of $45.45 and a one year high of $68.12 .
A total of 18 analysts have released a research note on AbbVie. Four analysts rating the company a strong buy, ten analysts rating the company a buy, five analysts rating the company a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $70.22.
About AbbVie (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.